It is known that NF-κB transcription factors are major drivers of most human cancers and yet there are no clinically useful NF-κB inhibitors to treat most of them, given the on-target toxicities of IKK/NF-κB targeting drugs. This evidence concerns the gene NFKB1 and cancer.